133 related articles for article (PubMed ID: 37178198)
1. CT-defined sarcopenia predicts treatment response in primary central nervous system lymphomas.
Surov A; Meyer HJ; Hinnerichs M; Ferraro V; Zeremski V; Mougiakakos D; Saalfeld S; Wienke A; Strobel A; Wolleschak D
Eur Radiol; 2024 Feb; 34(2):790-796. PubMed ID: 37178198
[TBL] [Abstract][Full Text] [Related]
2. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.
Cushen SJ; Power DG; Murphy KP; McDermott R; Griffin BT; Lim M; Daly L; MacEneaney P; O' Sullivan K; Prado CM; Ryan AM
Clin Nutr ESPEN; 2016 Jun; 13():e39-e45. PubMed ID: 28531567
[TBL] [Abstract][Full Text] [Related]
3. Body composition predictors of mortality on computed tomography in patients with spinal metastases undergoing surgical treatment.
Bongers MER; Groot OQ; Buckless CG; Kapoor ND; Twining PK; Schwab JH; Torriani M; Bredella MA
Spine J; 2022 Apr; 22(4):595-604. PubMed ID: 34699994
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Impact of Quality and Distribution of Adipose Tissue in Patients With Primary Central Nervous System Lymphoma.
Hinnerichs M; Ferraro V; Zeremski V; Mougiakakos D; Omari J; Pech M; Bär C; Wienke A; Saalfeld S; Strobel A; Surov A; Meyer HJ; Wolleschak D
In Vivo; 2022; 36(6):2828-2834. PubMed ID: 36309379
[TBL] [Abstract][Full Text] [Related]
5. The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients.
Basile D; Parnofiello A; Vitale MG; Cortiula F; Gerratana L; Fanotto V; Lisanti C; Pelizzari G; Ongaro E; Bartoletti M; Garattini SK; Andreotti VJ; Bacco A; Iacono D; Bonotto M; Casagrande M; Ermacora P; Puglisi F; Pella N; Fasola G; Aprile G; Cardellino GG
J Cachexia Sarcopenia Muscle; 2019 Apr; 10(2):368-377. PubMed ID: 30719874
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
[TBL] [Abstract][Full Text] [Related]
7. Quantitative muscle mass biomarkers are independent prognosis factors in primary central nervous system lymphoma: The role of L3-skeletal muscle index and temporal muscle thickness.
Leone R; Sferruzza G; Calimeri T; Steffanoni S; Conte GM; De Cobelli F; Falini A; Ferreri AJM; Anzalone N
Eur J Radiol; 2021 Oct; 143():109945. PubMed ID: 34492625
[TBL] [Abstract][Full Text] [Related]
8. Defining reference values for low skeletal muscle index at the L3 vertebra level based on computed tomography in healthy adults: A multicentre study.
Kong M; Geng N; Zhou Y; Lin N; Song W; Xu M; Li S; Piao Y; Han Z; Guo R; Yang C; Luo N; Wang Z; Jiang M; Wang L; Qiu W; Li J; Shi D; Li R; Cheung EC; Chen Y; Duan Z
Clin Nutr; 2022 Feb; 41(2):396-404. PubMed ID: 34999334
[TBL] [Abstract][Full Text] [Related]
9. Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer.
Caan BJ; Cespedes Feliciano EM; Prado CM; Alexeeff S; Kroenke CH; Bradshaw P; Quesenberry CP; Weltzien EK; Castillo AL; Olobatuyi TA; Chen WY
JAMA Oncol; 2018 Jun; 4(6):798-804. PubMed ID: 29621380
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Role of Low-Skeletal Muscle Mass on Staging Computed Tomography in Metastasized Colorectal Cancer: A Systematic Review and Meta-Analysis.
Meyer HJ; Strobel A; Wienke A; Surov A
Clin Colorectal Cancer; 2022 Sep; 21(3):e213-e225. PubMed ID: 35792019
[TBL] [Abstract][Full Text] [Related]
11. CT assessment of preoperative nutritional status in gastric cancer: severe low skeletal muscle mass and obesity-related low skeletal muscle mass are unfavorable factors of postoperative complications.
Fang Z; Du F; Shang L; Liu J; Ren F; Liu Y; Wu H; Liu Y; Li P; Li L
Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):317-324. PubMed ID: 33063547
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer.
Salinas-Miranda E; Deniffel D; Dong X; Healy GM; Khalvati F; O'Kane GM; Knox J; Bathe OF; Baracos VE; Gallinger S; Haider MA
Eur Radiol; 2021 Nov; 31(11):8662-8670. PubMed ID: 33934171
[TBL] [Abstract][Full Text] [Related]
13. Preoperative sarcopenia is associated with poor overall survival in pancreatic cancer patients following pancreaticoduodenectomy.
Peng YC; Wu CH; Tien YW; Lu TP; Wang YH; Chen BB
Eur Radiol; 2021 Apr; 31(4):2472-2481. PubMed ID: 32974690
[TBL] [Abstract][Full Text] [Related]
14. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
15. An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel.
Youn S; Chen A; Ha V; Chambers C; Eurich DT; McCall M; Sawyer MB
Clin Nutr; 2021 Aug; 40(8):4888-4892. PubMed ID: 34358833
[TBL] [Abstract][Full Text] [Related]
16. Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy.
Chu MP; Lieffers J; Ghosh S; Belch A; Chua NS; Fontaine A; Sangha R; Turner RA; Baracos VE; Sawyer MB
J Cachexia Sarcopenia Muscle; 2017 Apr; 8(2):298-304. PubMed ID: 27897411
[TBL] [Abstract][Full Text] [Related]
17. Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer.
Griffin OM; Duggan SN; Ryan R; McDermott R; Geoghegan J; Conlon KC
Pancreatology; 2019 Sep; 19(6):850-857. PubMed ID: 31362865
[TBL] [Abstract][Full Text] [Related]
18. Deep neural network for automatic volumetric segmentation of whole-body CT images for body composition assessment.
Lee YS; Hong N; Witanto JN; Choi YR; Park J; Decazes P; Eude F; Kim CO; Chang Kim H; Goo JM; Rhee Y; Yoon SH
Clin Nutr; 2021 Aug; 40(8):5038-5046. PubMed ID: 34365038
[TBL] [Abstract][Full Text] [Related]
19. Computed tomography-defined body composition as prognostic markers for unfavourable outcomes and in-hospital mortality in coronavirus disease 2019.
Meyer HJ; Wienke A; Surov A
J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):159-168. PubMed ID: 35018725
[TBL] [Abstract][Full Text] [Related]
20. CT-defined low-skeletal muscle mass as a prognostic marker for survival in prostate cancer: A systematic review and meta-analysis.
Meyer HJ; Wienke A; Surov A
Urol Oncol; 2022 Mar; 40(3):103.e9-103.e16. PubMed ID: 34483042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
